According to Lillys TRIUMPH-4 release, the most common adverse events with retatrutide were gastrointestinal: nausea diarrhea constipation vomiting decreased appetite Lilly also reported dysesthesia , an altered skin-sensation signal, in: 8.8% of participants on 9 mg 20.9% of participants on 12 mg compared with 0.7% on placebo Those events were generally mild and rarely led to discontinuation, but they are still notable because dysesthesia did not become a headline feature of the earlier semaglutide narrative
If Phase 3 trials are successful, Eli Lilly could potentially file for FDA approval in 2026, with approval possible in 2027
The pituitary gland: Inflammation here (hypophysitis) might cause headaches, hormonal problems, and other symptoms
McVey Neufeld KA, Luczynski P, Dinan TG, Cryan JF
TSH (thyroid-stimulating hormone): Hypothyroidism can mimic or worsen weight gain
There's no perfect diet